FDA Development of new stereoisomeric drugs

Titel:
FDA Development of new stereoisomeric drugs
Herkunft/Verlag:

Freedom of Information Staff, (HFI 35), Food and Drug Administration, Rm. 12 A - 30, 5600 Fishers Lane, Rockville, MD 20857, USA, http://www.fda.gov/cder/guidance

Dokumentenart:
FDA Guidance for Industry
Inhalt:
Development of new stereoisomeric drugs

Zurück

GMP Seminare nach Thema